1-20 of 127
Andrew W. Roberts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat
Journal: Blood
Blood (2024) 144 (Supplement 1): 3031.
https://doi.org/10.1182/blood-2024-199276
Published: 2024
Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Sun Loo, Harry Iland, Ing Soo Tiong, David Westerman, Jad Othman, Paula Marlton, Chong Chyn Chua, Duncan Purtill, Hannah Rose, Shaun Fleming, Deepak Singhal, Anoop K Enjeti, William S. Stevenson, Teng Fong Ng, McCulloch Derek, Lachlin Vaughan, Robin Gasiorowski, Adam Ivey, Amanda Souza, Revati Pattani, Natasha S. Anstee, Rachel Koldej, David S. Ritchie, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Andrew W. Roberts, Carolyn S. Grove, John Reynolds, Andrew H Wei
Journal: Blood
Blood (2024) 144 (Supplement 1): 223.
https://doi.org/10.1182/blood-2024-202895
Published: 2024
Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Nisha Thiagarajah, Mark R Dowling, Karin Dunne, Donna Aarons, Jenny Collins, Steven Tran, Shaun Fleming, Gaurav Sutrave, Devendra Hiwase, Chun Yew Fong, Blake Hsu, Duncan Purtill, Anne-Marie Watson, Glen A Kennedy, William S Stevenson, Stephen Robert Larsen, John Moore, Travis Perera, David S. Ritchie, Andrew Wei, Andrew W. Roberts, Nada Hamad, Ashish Bajel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3799.
https://doi.org/10.1182/blood-2024-209389
Published: 2024
Journal Articles

Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia

Meng-Xiao Luo, Tania Tan, Marie Trussart, Annika Poch, Minh-Hanh Thi Nguyen, Terence P. Speed, Damien G Hicks, Esther Bandala-Sanchez, Hongke Peng, Stephane Chappaz, Charlotte Slade, Daniel T Utzschneider, Rachel M Koldej, David Ritchie, Andreas Strasser, Rachel Thijssen, Matthew E Ritchie, Constantine Si Lun Tam, Geoffrey J Lindeman, David Ching Siang Huang, Professor, Thomas E Lew, Mary Ann Anderson, Andrew W Roberts, Charis E Teh, Daniel H D Gray
Journal: Blood
Blood blood.2024024341.
https://doi.org/10.1182/blood.2024024341
Published: 2024
Includes: Supplemental data
Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Clinical Trials & Observations Brief Report
Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A. Thompson, Glenda Burke, Mathias Bressel, Juliana Di Iulio, Rodney J. Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel Koldej, David Ritchie, Martin Dreyling, Mark A. Dawson, Sarah-Jane Dawson, John F. Seymour, Andrew W. Roberts, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (8): 867–872.
https://doi.org/10.1182/blood.2023023388
Published: 2024
Includes: Supplemental data
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Chong Chyn Chua, Natasha Anstee, Christoffer Flensburg, Charis Teh, Adam Ivey, Noorul Amin, Rachel Thijssen, Stefan K. Bohlander, Purvi M. Kakadia, Zhen Xu, Chun Yew Fong, Stephen Ting, Sun Loo, Ing Soo Tiong, Daniel Gray, Shaun Fleming, Nadia Davidson, Andrew W. Roberts, Ian Majewski, Andrew H. Wei, Fiona C. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 423.
https://doi.org/10.1182/blood-2023-185321
Published: 2023
Journal Articles

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, Mark Van Delft, Chris Riffkin, Georgiou Angela, Christine White, Yin Yuan, Jahja Michelle, Mary Ann Anderson, Rachel Thijssen, David C.S. Huang, Mark A Dawson, Andrew W. Roberts
Journal: Blood
Blood (2023) 142 (Supplement 1): 415.
https://doi.org/10.1182/blood-2023-184392
Published: 2023
Journal Articles

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Yin Yuan, Sarah T Diepstraten, Fiona C. Brown, Veronique Litalien, Andreas Strasser, Gemma L Kelly, Andrew W. Roberts, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (Supplement 1): 4163.
https://doi.org/10.1182/blood-2023-179698
Published: 2023
Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Clinical Trials & Observations
Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, Michael A. Dengler, Giovanna Pomilio, Natasha S. Anstee, Veronique Litalien, Ella Thompson, Thomas Morley, Sarah MacRaild, Ing S. Tiong, Rhiannon Morris, Karen Dun, Adrian Zordan, Jaynish Shah, Sebastien Banquet, Ensar Halilovic, Erick Morris, Marco J. Herold, Guillaume Lessene, Jerry M. Adams, David C. S. Huang, Andrew W. Roberts, Piers Blombery, Andrew H. Wei
Journal: Blood
Blood (2023) 141 (6): 634–644.
https://doi.org/10.1182/blood.2022016090
Published: 2023
Includes: Supplemental data
Journal Articles

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L. Garnham, Jafar S. Jabbari, Hongke Peng, Thomas E. Lew, Charis E. Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M. Djajawi, Constantine S. Tam, John F. Seymour, Piers Blombery, Daniel H.D. Gray, Ian J. Majewski, Matthew E. Ritchie, Andrew W. Roberts, David C.S. Huang
Journal: Blood
Blood (2022) 140 (20): 2127–2141.
https://doi.org/10.1182/blood.2022016040
Published: 2022
Includes: Supplemental data
Journal Articles

Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Ashley Whitechurch, Rory Bennett, Shafqat Inam, Benjamin Hartog, Rebecca Blackwood, Shevon Fernando, Felanita Hutani, Hadley Bortz, Mitchel Lincoln, Dennis Carney, Andrew W Roberts, Mary Ann Anderson, Constantine S. Tam, John F. Seymour
Journal: Blood
Blood (2022) 140 (Supplement 1): 9911–9912.
https://doi.org/10.1182/blood-2022-165609
Published: 2022
Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J. Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, Andrew W Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 3341–3343.
https://doi.org/10.1182/blood-2022-167837
Published: 2022
Journal Articles

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Chong Chyn Chua, Sun Loo, John Reynolds, Ing S Tiong, Chun Yew Fong, Stephen B Ting, Shaun Fleming, Andrew W Roberts, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 1708–1710.
https://doi.org/10.1182/blood-2022-165021
Published: 2022
Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Clinical Trials & Observations
Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood
Blood (2022) 139 (8): 1198–1207.
https://doi.org/10.1182/blood.2021012775
Published: 2022
Includes: Supplemental data
Journal Articles

Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Charis E Teh, Tania Tan, Marie Trussart, Mengxiao Luo, Rachel Thijssen, Andrew W Roberts, David C.S. Huang, Terence Speed, Mary Ann Anderson, Daniel Gray
Journal: Blood
Blood (2021) 138 (Supplement 1): 3710.
https://doi.org/10.1182/blood-2021-149938
Published: 2021
Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson
Journal: Blood
Blood (2021) 138 (13): 1089.
https://doi.org/10.1182/blood.2021012674
Published: 2021
Journal Articles

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang
Journal: Blood
Blood (2021) 138 (13): 1120–1136.
https://doi.org/10.1182/blood.2020006785
Published: 2021
Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Clinical Trials & Observations
Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts
Journal: Blood
Blood (2021) 138 (10): 836–846.
https://doi.org/10.1182/blood.2020009578
Published: 2021
Includes: Supplemental data
Journal Articles

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T. Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X. Shi, Michael A. Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S. Anstee, Boris Reljić, Sarah S. Gabriel, Tirta M. Djajawi, Chris D. Riffkin, Brandon J. Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, Giovanna Pomilio, Claudia Bruedigam, Axel Kallies, David A. Stroud, Ashish Bajel, Ruth M. Kluck, Steven W. Lane, Marie Schoumacher, Sébastien Banquet, Ian J. Majewski, Andreas Strasser, Andrew W. Roberts, David C. S. Huang, Fiona C. Brown, Gemma L. Kelly, Andrew H. Wei
Journal: Blood
Blood (2021) 137 (20): 2721–2735.
https://doi.org/10.1182/blood.2020010167
Published: 2021
Includes: Supplemental data